Forever grateful for all my mentors in IM and VM @ccfvascmed @CCF_IMCHIEFS for making me a better physician! CCF, you’ve been nothing short of stellar on all levels! @ClevelandClinic. To my wife, my backbone @fadel_remy a tremendous thank you! Next stop ➡️ Vanderbilt @VUMC_heart

Important data to guide shared decision making for patients with ascending aortic aneurysms below traditional surgical threshold #AortaEd @CleClinicHVTI @EricRoselliMD @PatrickVargoMD @LarsSvenssonMD @Dr_HaniNajm

Presented at #SVIN25: CREST-2: In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results: https://t.co/ZHLCV9ukNU Editorial:

CT Calcium Score of Zero- how useful is it? In ~2000 patients with a zero CT calcium score, 0.5% had coronary artery disease seen on CTA which did not affect prognosis. During a 13-year follow-up period, none died of a coronary event. https://t.co/3u1flsrWDo.

Presented at #AHA25: In a meta-analysis of 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full results: https://t.co/1LiJFFvnm3 @AHAScience

So… no more DAPT post CABG!!! (After Acute Coronary Sindrome). Aspirin vs DAPT: More major bleeding events, same MACE. #eacts2025 #CABG

Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias: @NEJM 🥸 The statement: "Keep K above 4 and Mg above 2" still holds: #ESCCongress2025 😱 Summary 👇👇👇

Beta-Blockers after Myocardial Infarction in Patients without Heart Failure: @NEJM @ESCCongress 🥸 Is evidence still in favor of beta blockers post AMI? #ESCCongress2025 😱Summary 👇👇👇

Even common diagnoses deserve an open mind. Check out our recently published case in JACC highlighting a rare pulmonary embolism (PE) mimicker. https://t.co/W4OPpU5ZBN

🩸 New insights from the RENOVE trial (extended duration anticoagulation) at #ISTH2025: 📉 Reduced-dose DOAC is non-inferior in patients with BMI <30, with less bleeding risk. ⚠️ But in patients with BMI ≥30, reduced-dose may be inferior for bleeding and recurrent VTE. ➡️

Is this the end of rivaroxaban for acute VTE? @LanaCastellucci presenting the COBBRA trial - 1st RCT comparing apixaban to riva over 3 months. 56% reduction in bleeding risk with apixaban. A safer Rx with the same efficacy. #ISTH2025

Reevaluating Beta-Blocker Recommendations Post-Myocardial Infarction: Perspective on the 2025 Guideline Update: @JACCJournals 🥸Commentary on the guidelines - early beta blocker use post MI - 😱@MichaelGNanna wrote extensively on this in older pts. 🥸Take a look 👇👇👇

#Spironolactone vs #Amiloride for Resistant Hypertension A Randomized Clinical Trial N = 118 (1:1 randomization) 📍 12-week home #SBP ↓:  • Amiloride: −13.6 mm Hg  • Spironolactone: −14.7 mm Hg 📍 Between-group difference: −0.68 mm Hg (90% CI −3.50 to 2.14) ✅

In this #JACCINT pooled analysis of pts w/ left main #SCAD, death occurred in 9%, recurrent MI in 13%, urgent #revascularization in 21%, & #LVAD/heart transplant in 4% at 120 days. Early revascularization significantly reduced these risks! https://t.co/gpptzcEucn #HeartTx #cvMI

One of the most important trials at @ACCinTouch #ACC25 ! Compared fluid restriction to liberal approach in #HeartFailure. Why? This affects individuals w/HF EVERY DAY! ✨No benefit of Fluid Restriction ✨No HARM for liberal fluid intake ✨Improved QOL in liberal fluid intake

#ACC25 #STRIDE examined Semaglutide in PAD #LBCT 👟function impairment is common in PAD with limited Tx 👟93% completed trial, 1/3 women,~ BMI 28, functionally limited (0.1/mile) 👟Sema 💉🆚UC in T2DM+symptoms PAD: walking distance ⤴️ by 13% out to 1 year🤯💥

Rivawar trial: Warfarina vs rixarobaxan en pacientes con trombo intraventricular post infarto.#ACC25 ➡️Hipótesis: no inferioridad en términos de resolución de trombo a las 12 semanas ➡️261 pacientes Similar resolución de trombo entre ambos, sin diferencias en seguridad

BREAKING from @NEJM In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is : 🔘Noninferior to full-dose (5 mg BID) for VTE recurrence 🔘Lower bleeding risk (12.1% vs. 15.6%) 🔘Safer extended anticoagulation, same protection.

“…individuals with CAC=0 and thoracic aortic calcium [TAC] ≥500 experienced CVD events approaching 20 per 1,000 person years.”

Original Article: Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation (AZALEA–TIMI 71 trial) https://t.co/CrHwsbmXMt Science behind the Study: Uncoupling Thrombosis and Hemostasis by Inhibiting Factor XI https://t.co/PFU6lOfP7X #Cardiology

🫀Tackling worsening #HFrEF requires a paradigm shift! 💊Rapid initiation of quadruple therapy is vital 🩸Quintuple therapy w/vericiguat & IV Iron can reduce clinical risk and improve pt outcomes https://t.co/bnhEAsXDO5 @JACCJournals @SrihariNaiduMD @RichardAFerraro @DLBHATTMD